

Part Two: Drs. Dahiya, Spiegel Return to Discuss 'Black Box' Warning on CAR-T Therapies
Feb 29, 2024
In this podcast, Drs. Dahiya and Spiegel discuss the FDA's 'Black Box' warning on CAR-T therapies for blood cancer patients. They explore the risks of secondary malignancies post-treatment and the impact of shifting CAR-T therapies to frontline treatments. The speakers stress the importance of informed consent, patient counseling, and evaluating the benefit-risk ratio in oncology treatments.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
FDA Warning on Secondary Malignancies Post CAR T cell Therapy
02:14 • 13min
Exploring the Impact of Shifting CAR-T Therapies to Frontline Treatments and Study Findings
15:20 • 3min
Exploring Secondary Malignancies in CAR-T Therapy
17:54 • 11min
Exploring the Benefit-Risk Ratio of CAR-T Cell Therapy in Approved Settings
28:30 • 3min